ZyhCG 2000 (HCG 2000iu) – Product Overview

ZyhCG 2000 is a pharmaceutical preparation that contains Human Chorionic Gonadotropin at a potency of 2000 International Units per vial. The product is supplied by German Remedies Private Ltd and is indicated for the treatment of female infertility associated with ovulatory dysfunction. Each package includes a single vial sealed in a protective box, and the available pack sizes are 3, 6, or 9 vials, allowing clinicians to tailor the quantity to the duration of therapy. The formulation is intended for intramuscular or subcutaneous administration under medical supervision and is stored refrigerated until use. ZyhCG 2000 is classified within the category of female infertility treatments and is registered under the active ingredient Human Chorionic Gonadotropin.

What is ZyhCG 2000 (HCG 2000iu)

Human Chorionic Gonadotropin, commonly abbreviated as HCG, is a glycoprotein hormone produced by the placenta during pregnancy. In clinical practice, exogenous HCG mimics the natural hormone and stimulates the same receptors found on ovarian cells, thereby promoting the final maturation of ovarian follicles and triggering ovulation. The 2000iu strength indicates the amount of biologically active hormone present in each vial, a dosage that is frequently employed in controlled ovarian stimulation protocols. ZyhCG 2000 is manufactured to pharmaceutical quality standards and undergoes rigorous testing for purity, potency, and sterility. The hormone is supplied as a lyophilized powder that must be reconstituted with a sterile diluent before administration, ensuring that the active component remains stable until the point of injection.

Uses and Benefits

Clinicians prescribe ZyhCG 2000 primarily to induce ovulation in women who do not regularly release mature eggs, a condition known as anovulation. By stimulating the luteinizing hormone surge, the medication increases the likelihood of egg release, which can then be fertilized naturally or with assisted reproductive techniques such as intrauterine insemination. In addition to its ovulation‑inducing action, HCG supports the corpus luteum, helping to maintain the early phase of pregnancy and reducing the risk of luteal phase deficiency. The benefits of using ZyhCG 2000 include a well‑characterized safety profile, predictable pharmacokinetic behavior, and the convenience of a single‑dose vial that simplifies dosing schedules. When combined with lifestyle modifications and fertility counseling, the therapy can improve conception rates in appropriately selected patients.

How It Works

The mechanism of action of ZyhCG 2000 is rooted in its ability to bind to the LH‑FSH receptors on the surface of ovarian granulosa and theca cells. This binding mimics the endogenous luteinizing hormone surge that naturally occurs mid‑cycle, leading to the final maturation of the dominant follicle and the release of the oocyte from the ovarian wall. The hormone also stimulates the production of progesterone by the corpus luteum, which prepares the endometrium for implantation. Because HCG has a similar structure to LH, it elicits a potent but transient response, typically peaking within hours after injection and then declining. This pharmacodynamic profile makes ZyhCG 2000 an effective trigger for ovulation when administered at the appropriate follicular size, as confirmed by ultrasound monitoring.

Dosage Guidelines

Dosage of ZyhCG 2000 is individualized based on the patient’s follicular development, hormonal profile, and medical history. In most protocols, a single intramuscular or subcutaneous injection of the entire 2000iu vial is administered once the leading follicle reaches a mean diameter of 18‑20 mm on ultrasound, and when serum estradiol levels are within an acceptable range. The exact timing is determined by the treating physician, who may adjust the trigger point to optimize the chance of successful ovulation while minimizing the risk of ovarian hyperstimulation syndrome. Patients are advised to follow the injection instructions provided by their healthcare professional, to use a sterile needle, and to rotate injection sites to reduce tissue irritation. Any unused reconstituted solution should be discarded according to local regulations. For more detailed protocols, see the National Institutes of Health resource on HCG usage (National Institutes of Health).

Side Effects

Like all medicinal products, ZyhCG 2000 can be associated with adverse effects, although many are mild and self‑limiting. Commonly reported side effects include mild abdominal discomfort, bloating, and transient injection‑site reactions such as redness or swelling. Some women experience headache, breast tenderness, or mood fluctuations, which typically resolve without medical intervention. Rarely, more serious complications such as ovarian hyperstimulation syndrome, allergic reactions, or thromboembolic events have been documented, especially when higher doses or multiple treatment cycles are used. Patients should be instructed to seek immediate medical attention if they experience severe pelvic pain, shortness of breath, visual disturbances, or signs of a severe allergic reaction such as swelling of the face or throat.

Warnings and Precautions

ZyhCG 2000 must be used only under the supervision of a qualified infertility specialist, as improper use can lead to hormonal imbalances and unintended pregnancies. The medication is contraindicated in individuals with known hypersensitivity to HCG or any of the excipients, as well as in patients with active or suspected ovarian, breast, or uterine cancers. Caution is advised for women with a history of thromboembolic disorders, severe liver disease, or uncontrolled thyroid disease, since hormonal modulation may exacerbate these conditions. Pregnant women should not receive ZyhCG 2000, and a pregnancy test is recommended before initiating therapy. It is also important to store the vials in a refrigerator (2‑8 °C) and to avoid exposure to direct sunlight, which can degrade the hormone and reduce efficacy. The U.S. Food and Drug Administration (FDA) provides additional guidance on the use of fertility hormones.

Frequently Asked Questions

1. What is the recommended storage condition for ZyhCG 2000?

   ZyhCG 2000 must be stored refrigerated at 2‑8 °C and protected from light until use. Once reconstituted, the solution can be kept at room temperature for a limited period, typically no more than 24 hours, after which it should be discarded. Proper storage ensures that the hormone retains its potency and reduces the risk of degradation that could affect efficacy.

2. How long does it take for the hormone to be cleared from the body?

   After administration, the exogenous HCG is metabolized similarly to endogenous luteinizing hormone, with a typical half‑life of approximately 28‑36 hours. Complete clearance from the circulation usually occurs within about five to six days, although trace amounts may be detectable for up to ten days depending on individual metabolism and renal function.

3. Can ZyhCG 2000 be used in combination with other fertility drugs?

   Yes, ZyhCG 2000 is frequently used alongside gonadotropins or clomiphene citrate in assisted reproductive protocols. When combined with other ovulation‑inducing agents, clinicians monitor follicular response closely to adjust dosages and avoid excessive ovarian stimulation. The decision to combine therapies is based on the patient’s specific fertility profile and the physician’s treatment plan.

4. Is a prescription required to purchase ZyhCG 2000?

   ZyhCG 2000 is a prescription‑only medication in most jurisdictions, including India where it is marketed by German Remedies Private Ltd. A qualified healthcare provider must evaluate the patient’s medical history and perform necessary assessments before prescribing the drug. This regulatory requirement ensures that the therapy is appropriate and safe for each individual.

5. What should I do if I miss the scheduled ovulation trigger?

   If the scheduled trigger injection is missed, the treating physician should be contacted promptly. In many protocols, a new trigger can be administered once the attending clinician confirms that the follicle size and hormone levels remain within the acceptable range. Self‑adjusting the dose without professional guidance is not recommended, as it may affect the chances of successful ovulation.

Related Products

• Azelastine Nasal Spray (Generic)
• Arzep Nasal Spray (Azelastine)
• Vigora 100 mg (Sildenafil Citrate)
• Vigora Tablet (Sildenafil Citrate)
• Vigora Lido Spray (Lidocaine)
• Vigore Gold 100 mg (Sildenafil Citrate)
• Vigore Force 80 mg (Sildenafil/Dapoxetine)
• Tadora 20 mg (Tadalafil)
• Vigora 50 mg (Sildenafil Citrate)
• Tadora Force 80 mg(Tadalafil/Dapoxetine)
• ZyhCG 10000 (HCG 10000iu)
• ZyhCG 5000 (HCG 5000iu)